BEACTICA THERAPEUTICS AB

Their core work

Beactica Therapeutics is a Swedish biotech SME based in Uppsala that specializes in fragment-based drug discovery and targeted protein degradation. They develop therapeutic approaches targeting the ubiquitin-proteasome system, including PROTACs (proteolysis-targeting chimeras) — a rapidly growing class of drugs that selectively destroy disease-causing proteins. Their work bridges structural biology and medicinal chemistry to design compounds that modulate protein interactions, with applications in oncology including glioblastoma treatment.

What they specialise in

How they've shifted over time

Beactica's trajectory shows a clear shift from foundational drug discovery training toward highly specific targeted degradation science. Their early involvement (2016) in FRAGNET focused on fragment-based screening methods as part of a broad training network. By 2018-2019, they had sharpened their focus significantly — coordinating their own glioblastoma therapeutics feasibility study and joining UBIMOTIF, which targets the ubiquitin-proteasome pathway and PROTACs, one of the hottest areas in modern drug development.

Beactica is moving from general screening services toward specialized targeted protein degradation — expect future work in PROTAC design, molecular glues, and ubiquitin pathway therapeutics.

How they like to work

Beactica operates primarily as a specialist partner in research consortia (2 of 3 projects), but has also demonstrated the ability to lead as coordinator on their SME Instrument project. With 21 unique partners across 12 countries from just 3 projects, they are well-connected for a small company and comfortable working in large international consortia. Their mixed participation profile suggests they contribute deep technical expertise to larger teams while pursuing their own commercial R&D agenda independently.

Despite only 3 H2020 projects, Beactica has built a surprisingly broad network of 21 partners across 12 countries — largely through participation in the FRAGNET and UBIMOTIF training networks, which are inherently multi-partner. This gives them strong academic connections across European structural biology and medicinal chemistry communities.

What sets them apart

Beactica sits at the intersection of fragment-based screening and targeted protein degradation — two approaches that are converging in modern drug discovery. As a Swedish SME with both consortium experience and its own commercial pipeline (glioblastoma), they offer a rare combination: academic-grade biophysical expertise packaged in a company that understands commercial drug development timelines. For consortium builders, they bring hands-on screening capabilities that bridge the gap between academic target discovery and pharmaceutical lead optimization.

Highlights from their portfolio

• EpiGlioT
  Their only coordinator role — an SME Instrument Phase 1 project on glioblastoma, signaling they have their own commercial therapeutic pipeline beyond service work.
• UBIMOTIF
  Largest funded project (EUR 281,983) focusing on PROTACs and ubiquitin system — positions them in one of pharma's fastest-growing therapeutic modalities.
• FRAGNET
  Pan-European training network in fragment-based drug discovery that established Beactica's broad partner network across 12 countries.